Palabras clave
Hanseniasis
Chemotherapy
Hansenic neuritis
Erythema nodosum hansenicum
Chemotherapy
Hansenic neuritis
Erythema nodosum hansenicum
Cómo citar
1.
CARAYON A. La chimiotherapie anti-hansénienne face a la névrite (orientations nouvelles). Hansen. Int. [Internet]. 30 de junio de 1977 [citado 23 de noviembre de 2024];2(1):24-46. Disponible en: https://periodicos.saude.sp.gov.br/hansenologia/article/view/35655
Resumen
The mechanisms of activity of chemotherapy, immunotherapy, antibiotic therapy and surgery in hansenic neuritis are presented. The clinical, bacteriological and pathological pictures of the different types, varieties and stages of neuritis are described and should serve as a guide for the institution of the appropriate therapeutical measures.
Citas
1 . ALLEN, B. W.; ELLARD, G. A.; GAMMON, P. J. The penetration of Dapsone, Rifampicin, Isonoazid and Pyrazinamide into peripheral nerves. Br. J. Pharmacol., 55: 151-155, 1975.
2. BANERJEE, D. K.; ELLARD, G. A.; GAMM ON, P. T.; WATERS, M. F. R. Some observations on the pharmacology, of clofazimine (B663). Am. J. Trop. Med. Hyg., 23 (6): 1110-1115, 1974.
3. BARNETSON, R.; BRINE, G.; PEARSON, J. M. H.; KRONVALL, G Cell mediated and humoral immunity `Reversal reactions" Int. J. Lepr., 44(1/2): 267-274, 1976.
4, BARNETSON, R.; PEARSON, J. M. H.; REES, R. J. W. Evidence for prevention of bordeline leprosy reactions by dapsone. Lancet, 2 (7996): 1171-1172, 1976.
5. BEIGUELMAN, B. & PISANI, R. C. B. Effect of DDS phytohemagglutinin-induced lymphocyte transformation. Int. J. Lepr., 42 (4) : 412-415, 1974.
6. BROWNE, S. G. The drug treatment of leprosy. Practitioner, 2/5(1288): 493-500, 1975.
7. BRYCESON, A. & PFALTZGRAFF, R. E. Leprosy for students of medicine. Livingston, Churcill. p. 76-86.
8. BUFFINGTON, G. A.; DOMINGUEZ, J. H.; PIERING, W. F.; HEBERT, L. A.; KAUFFMAN, H. M.; LEMANN JR., J. Interaction of rifampin and glucocorticoids. JAMA, 236(17): 1958-1960, 1976.
9. CARAYON, A. Limites actuelles de la chimiothérapie anti-hansénienne sur la névrite et danger de ses effects secondaires immunologiques. Méd. Trop., 36(1): 86-96, 1976; Méd. Afr. Noire, 23(10): 567-577, 1976.
10. CAYLEY, F. E. & MAJUMDAR, S. K. Ocular toxicity due to rifampicin. London, Pharmaceutical Press, 1972. p. 1416.
11. CHANALET, G.; GUYON, J.; BEAUTE, J.; PARC, F.: BOUTIER, F. Premiers résultats du traitement de la lèpre en Nouvelle-Calédonié par la rifampicine. Méd. Trop. 32(2): 203-215, 1972.
12. CHASSAGNON, C. Pathologie médicamenteuse en rapport avec l'usage des corticoides et des anti-inflammatoires. J. Med. Lyon, 57(1309): 631-638, 1976.
13. CLINICAL aspects of the blood-brain barrier. Br. Med. J., 2(6028): 133, 176 (Editorial)
14. COLLINS, G. et al. Chloroquine as prostaglandin antagonist in treatment of patient ductus arteriosus. Lancet, 2(7989): 810, 1972.
15. CONSTABLE, T. J. & McCONKEV, B. Borderline leprosy reactions and dapsone. Lancet, 1 (8001): 44-45, 1977.
16. DAJANI, B. M.; CANADY, M. S.; THOMPSON, J. S.; KASIK, J. E. Rifampicin: an immuno suppressant? Lancet, 2: 1094, 1972.
17. DESIKAN, K. V. & BALAKRISHNAN, S. Tissue levels of clofazimine in a case of leprosy. Lepr. Rev., 47: 107-113, 1976.
18. DURIEZ, J. TRIAU, R.; DEBEAUMONT, A,; LE CAMPION, T. Effet immuno-dépresseur de la rifampicine et vaccination contre la rubéole. Nouv. Presse Méd., 3: 752, 1974.
19. EKAMBARAM, V. & VENKATACHARI, S. A trial of long-acting sulphonamide R. O. 4-4393 (Fanasil) in treatment of cases of lepromatous leprosy with repeated ENL. Leprosy India, 48(1): 24-30, 1976.
20. GARROD Antibiotic and chemotherapy. 3ème éd. Livingston, Churchill, 1971.
21. GATTI, J. C. Combined therapy in leprosy. Lepr. Rev., 46(suppl.): 155-160, 1975.
22. GATTI, J. C. Presente y futuro en la terapeutica de la lepra Publ. Cent. Est. Leprol., 15 (1/2): 49-63, 1975.
23. GELBER, R. H. & REES, R. J. W. Dapsone metabolism in patients with dapsone-resistant leprosy. Am. I. Trop. Med. Hyg., 24(6 pt. 1): 963-967, 1975.
24. GELBER, R. H.; RESS, R. J. W.; GRASSI, G. G.; POZZI, E. Effect of rifampicin on delayed-hypersensitivity reactions. I. Infect. Dis., 126:542-544, 1972.
25. GUIBERT, J. Sulfamides. Maladies Infectieuses, 2-1976-C.
26. HADDEN, J. W.; SADLIK, J. R.; HADDEN, E. M. Macrophage proliferation induced in vitro by a lymphocyte factor. Nature, 257: 483-485, 1975.
27. HASS, C. & LEBAS, F. X. Rifampicine et contraception orale inefficace. Antibiotherapie antituberculeuse. Etude analytique, Poumon. 1 ère Ed. 11. 1977-C.
28. HASTINGS, R. C.; JACOBSON, R. R.; TRAUTMAN, J. R. Long-termclinicaltoxicitystudies with clofazimine (B663) in leprosy. Int. J. Lepr., 44(3): 287-293, 1976.
29. HASTINGS, R. C.; MORALES, M. J.; SHANNON, E. J.; JACOBSON, R. R. Preliminaryresults on the safety and efficacy of transfer factor in leprosy. Int. J. Lepr., 44(1/2): 275, 1976.
30. HAVEL, A. & ROSENFELD, M. Potenzierung der Wirkung von Rifampicin and Ethionamid durch das gegen M. tuberculosis unwirksame 4,4-Diamino-Diphenylsulfon (DDS) in vitro. Prax. Pneumol., 29(8): 453-458, 1975.
31. HOGERZEIL, L. M. & PRABHUDAS, N. The effect of long-term steroid therapy on patients treatment with clofazimine (Lamprene). Lepr. Rev., 46 (suppl.). 111-115, 1975.
32. JACOBSON, R. R. & HASTINGS, R. C. Rifampin-resistant leprosy. Lancet, 1, 1977.
33. JIMENEZ DE ASUA, L. et al. Specific glucocorticoid inhibition of growth promoting effects of prostaglandin F,, on 3T3 cells. Nature, 265:450-452, 1977.34. JOPLING, W. H. Borderline leprosy reactions and dapsone. Lancet, 1(8001) : 44, 1977.
35. JUY, D. & CHEDID, L. Comparison between macrophage activation and enhancement of nonspecific resistance to tumors by mycobacterial immunoadjuvants. Proc. Nat. Acad. Sci. USA, 72(10): 4105-4109, 1975.
36. KARAT, A. B. A. Long-term follow-up of clofazimine (Lamprenne) in the management of reactive phases of leprosy. Lepr. Rev., 46(suppl.): 105-109, 1975.
37. KARAT, A. B. Low dose dapsone therapy in lepromatous leprosy. Lepr. Rev., 46(suppl.) 89-92, 1975.
38. LANGUILLON, J. Treatment of leprosy with clofazimine rifampicin and bayrena. Lepr. Rev., 46(suppl.): 81-84, 1975.
39. LEBAS, F. C.; HASS, C.; CHOUBRAC P. Heparotoxicité de l'association rifampicine-isoniazide. Antibiothérapie antituberculeuse. Etude analytique. Poumon lère Ed. 11.1976-C.
40. LEIKER D. L. Chemotherapy in leprosy. Int. J. Dermatol., 14(4) : 254-262, 1975.
41. LEIKER, D. L. Effect of mono treatment and combined treatment on the morphology of Myco-leprae in the skin. Lepr. Rev., 46 (suppl.): 73-79, 1975.
42. L EN Z IN I , L . Immunitá all'infezione: problematica ancora attuale. G. Batteriol. Virol. Immunol., 67(7-12): 308-316, 1974.
43. LEVY, L. Treatment failure in leprosy. Public Health Service Hospital, San Francisco. Int. J. Lepr., 44(1/2): 177-182, 1976.
44. LEVY, L.; SHEPARD, C. C.; FASAL, P. The bactericidal effect of rifampicin on M. leprae in man: a) single doses 600, 900 and 1200 mg and b) baily doses of 300 mg. Int. J. Lepr., 44(1/2): 183-187, 1976.
45. MANSFIELD, R. E. Tissue concentrations of clofazimine (B663) in man. Am. J. Trop. Med. Hyg., 23(6): 1116-1119, 1974.
46. MAYNARD, E. A.; SCHULTZ, R. L.; PEASE, D. C. Electron microscope of the vascular bed of rat cerebral cortex. Am. J. Anatol., 100(3): 409-433, 1957.
47. MEHRA, N. K.; DASGUPTA, A.; VAIDYA, M. C. An evaluation of the immune state in leprosy. Leprosy India, 48(3): 231-237, 1976.
48. MORRISON, N. E. & MARLEY, G. M. The mode of action of clofazimine. DNA blinding studies. Int. J. Lepr. 44(1/2): 133-134, 1976.
49. OPROMOLLA, D.V.A. & TONELLO, C. J. S. Antibiotics in leprosy, with special reference to rifampicin. Lepr. Rev., 46(suppl.): 141-145, 1975.
50. PAUNESCU, E. In vivo and in vitro suppression of humoral and cellular immunological response by rifampicin. Nature, 228: 1188-1190, 1970.
51. PEARSON, J. M. H.; REES, R. J. W.; WATERS, M. F. S. Sulphone resistance in leprosy. Lancet, 2(7924). 69-72, 1975.
52. PETERS, J. H. Carcinogenic activity of dapsone. Int. J. Lepr., 44(3): 383-384, 1976.
53. PFALTZGRAFF, R. E. The control of neuritis in leprosy with clofazimine. Int. J. Lepr., 40(4): 392-398, 1972.
54. RAMANUJAM, K.; IYER, C. G. S.; RAMU, G. A report on a controlled clinical trial with conventional and one third conventional dose of dapsone administered orally once a week in lepromatous patients. Lepr. Rev., 46(suppl.): 93-97, 1975.
55. RAMPEN, F. Rifampicin in the treatment of reactions in leprosy. Lepr. Rev., 47:75-76, 1976.
56. REA, T. H. & LEVAN, N. E. Erythema nodosum leprosum in a general hospital. Arch. Dermatol., 111(12) : 1575-1580, 1975.
57. REES, R. J. W. Rifampicin: the investigations of a bactericidal antileprosy drug. Lepr. Rev., 46(suppl.): 121-124, 1975.
58. REES, R. J. W.; WATERS, W. F. R.; PEARSON, J. M. H.; HELMY, H. S.; LAING, A. B. G. Long-term treatment of dapsone-resistant leprosy with rifampicin: clinical and bacteriological studies. Int. J. Lepr., 44(1/2): 159-169, 1976.
59. RUBEN, F. L.; WINKELSTEIN, A.; FOTIADIS, I. G.; DESSAUER, P. Rifampicin and immunosuppression. Lancet, 2(7835): 978, 1973.
60. SANSARRICQ, H.; TORRIGIANI, G.; WALTER, J,; REES, R. J. W. The WHO program for research on immunology of leprosy (IMMLEP). Int. I. Lepr., 44(1/2): 276-283, 1976.
61. SERROU, B.; SOLASSOL, C.; KARCENTY, L.; JOYEUX, H.; PUJOL, H. Action immunodépressive de la rifampicine. Nouv. Presse Med., /(19): 1295, 1972.
62. SHEPARD, C. C. Rifampicin therapy of lepromatous leprosy. Am. 1. Trop. Med. Hyg., 24(3): 475-484, 1975.
63. SHEPARD, C. C.; ELLARD, G. A.; LEVY, L.; OPROMOLLA, D. V. A.; PATTYN, S. R.; PETERS, J. H.; REES, R. J. W.; WATERS, M. F. R. Chimiothérapie experimentale de la lèpre. Bull. WHO, 54(3): 235-244, 1976.
64. SHER, R.; HOLM, G.; KOK, S. K.; KOORNHOF, H. J.; GLOVER, A. T and CR -I- lymphocyte profile in leprosy and the effect treatment. Infec. Immun., 13(1): 23-35, 1976.
65. SHESKIN, J. The case for invisible leprosy. J. Int. Dermatol., 14(5): 345-346, 1975.
66. SIBILLE, M. Tableau de famille des antibiotiques ou comment choisir votre antibiotique. Cah. Med., /(22): 1493-1515, 1976.
67. STEVENSON, R. D. Mechanism of anti-inflammatory. Action of glucocorticosteroids. Lancet, 1(8005): 225-226, 1977.
68. USTACELEBI, S. & WILLIAMS, J. F. Depression of interferon production in chick embryo cells by rifampicin. 1. Gen. Viral., 15: 139-148, 1972.
69. VILDE, J. L. Les associations d'antibiotiques. Encyclopédie Médico-Chir.
70. YAMADA, S. & KAZUYOSHI, I. Induction of hepatic ortiso-6-hydroxylase by rifampicin. Lancet, 2(7981): 366-367, 1976.
71. YOUMANS, S.; YOUMANS, G. P.; CAHALL, D. Effect of rifampicin on immunity to tuberculosis and on delayed hypersensitivity to purified protein derivative. Infect. Immun. 3(1): 127-132, 1976.
2. BANERJEE, D. K.; ELLARD, G. A.; GAMM ON, P. T.; WATERS, M. F. R. Some observations on the pharmacology, of clofazimine (B663). Am. J. Trop. Med. Hyg., 23 (6): 1110-1115, 1974.
3. BARNETSON, R.; BRINE, G.; PEARSON, J. M. H.; KRONVALL, G Cell mediated and humoral immunity `Reversal reactions" Int. J. Lepr., 44(1/2): 267-274, 1976.
4, BARNETSON, R.; PEARSON, J. M. H.; REES, R. J. W. Evidence for prevention of bordeline leprosy reactions by dapsone. Lancet, 2 (7996): 1171-1172, 1976.
5. BEIGUELMAN, B. & PISANI, R. C. B. Effect of DDS phytohemagglutinin-induced lymphocyte transformation. Int. J. Lepr., 42 (4) : 412-415, 1974.
6. BROWNE, S. G. The drug treatment of leprosy. Practitioner, 2/5(1288): 493-500, 1975.
7. BRYCESON, A. & PFALTZGRAFF, R. E. Leprosy for students of medicine. Livingston, Churcill. p. 76-86.
8. BUFFINGTON, G. A.; DOMINGUEZ, J. H.; PIERING, W. F.; HEBERT, L. A.; KAUFFMAN, H. M.; LEMANN JR., J. Interaction of rifampin and glucocorticoids. JAMA, 236(17): 1958-1960, 1976.
9. CARAYON, A. Limites actuelles de la chimiothérapie anti-hansénienne sur la névrite et danger de ses effects secondaires immunologiques. Méd. Trop., 36(1): 86-96, 1976; Méd. Afr. Noire, 23(10): 567-577, 1976.
10. CAYLEY, F. E. & MAJUMDAR, S. K. Ocular toxicity due to rifampicin. London, Pharmaceutical Press, 1972. p. 1416.
11. CHANALET, G.; GUYON, J.; BEAUTE, J.; PARC, F.: BOUTIER, F. Premiers résultats du traitement de la lèpre en Nouvelle-Calédonié par la rifampicine. Méd. Trop. 32(2): 203-215, 1972.
12. CHASSAGNON, C. Pathologie médicamenteuse en rapport avec l'usage des corticoides et des anti-inflammatoires. J. Med. Lyon, 57(1309): 631-638, 1976.
13. CLINICAL aspects of the blood-brain barrier. Br. Med. J., 2(6028): 133, 176 (Editorial)
14. COLLINS, G. et al. Chloroquine as prostaglandin antagonist in treatment of patient ductus arteriosus. Lancet, 2(7989): 810, 1972.
15. CONSTABLE, T. J. & McCONKEV, B. Borderline leprosy reactions and dapsone. Lancet, 1 (8001): 44-45, 1977.
16. DAJANI, B. M.; CANADY, M. S.; THOMPSON, J. S.; KASIK, J. E. Rifampicin: an immuno suppressant? Lancet, 2: 1094, 1972.
17. DESIKAN, K. V. & BALAKRISHNAN, S. Tissue levels of clofazimine in a case of leprosy. Lepr. Rev., 47: 107-113, 1976.
18. DURIEZ, J. TRIAU, R.; DEBEAUMONT, A,; LE CAMPION, T. Effet immuno-dépresseur de la rifampicine et vaccination contre la rubéole. Nouv. Presse Méd., 3: 752, 1974.
19. EKAMBARAM, V. & VENKATACHARI, S. A trial of long-acting sulphonamide R. O. 4-4393 (Fanasil) in treatment of cases of lepromatous leprosy with repeated ENL. Leprosy India, 48(1): 24-30, 1976.
20. GARROD Antibiotic and chemotherapy. 3ème éd. Livingston, Churchill, 1971.
21. GATTI, J. C. Combined therapy in leprosy. Lepr. Rev., 46(suppl.): 155-160, 1975.
22. GATTI, J. C. Presente y futuro en la terapeutica de la lepra Publ. Cent. Est. Leprol., 15 (1/2): 49-63, 1975.
23. GELBER, R. H. & REES, R. J. W. Dapsone metabolism in patients with dapsone-resistant leprosy. Am. I. Trop. Med. Hyg., 24(6 pt. 1): 963-967, 1975.
24. GELBER, R. H.; RESS, R. J. W.; GRASSI, G. G.; POZZI, E. Effect of rifampicin on delayed-hypersensitivity reactions. I. Infect. Dis., 126:542-544, 1972.
25. GUIBERT, J. Sulfamides. Maladies Infectieuses, 2-1976-C.
26. HADDEN, J. W.; SADLIK, J. R.; HADDEN, E. M. Macrophage proliferation induced in vitro by a lymphocyte factor. Nature, 257: 483-485, 1975.
27. HASS, C. & LEBAS, F. X. Rifampicine et contraception orale inefficace. Antibiotherapie antituberculeuse. Etude analytique, Poumon. 1 ère Ed. 11. 1977-C.
28. HASTINGS, R. C.; JACOBSON, R. R.; TRAUTMAN, J. R. Long-termclinicaltoxicitystudies with clofazimine (B663) in leprosy. Int. J. Lepr., 44(3): 287-293, 1976.
29. HASTINGS, R. C.; MORALES, M. J.; SHANNON, E. J.; JACOBSON, R. R. Preliminaryresults on the safety and efficacy of transfer factor in leprosy. Int. J. Lepr., 44(1/2): 275, 1976.
30. HAVEL, A. & ROSENFELD, M. Potenzierung der Wirkung von Rifampicin and Ethionamid durch das gegen M. tuberculosis unwirksame 4,4-Diamino-Diphenylsulfon (DDS) in vitro. Prax. Pneumol., 29(8): 453-458, 1975.
31. HOGERZEIL, L. M. & PRABHUDAS, N. The effect of long-term steroid therapy on patients treatment with clofazimine (Lamprene). Lepr. Rev., 46 (suppl.). 111-115, 1975.
32. JACOBSON, R. R. & HASTINGS, R. C. Rifampin-resistant leprosy. Lancet, 1, 1977.
33. JIMENEZ DE ASUA, L. et al. Specific glucocorticoid inhibition of growth promoting effects of prostaglandin F,, on 3T3 cells. Nature, 265:450-452, 1977.34. JOPLING, W. H. Borderline leprosy reactions and dapsone. Lancet, 1(8001) : 44, 1977.
35. JUY, D. & CHEDID, L. Comparison between macrophage activation and enhancement of nonspecific resistance to tumors by mycobacterial immunoadjuvants. Proc. Nat. Acad. Sci. USA, 72(10): 4105-4109, 1975.
36. KARAT, A. B. A. Long-term follow-up of clofazimine (Lamprenne) in the management of reactive phases of leprosy. Lepr. Rev., 46(suppl.): 105-109, 1975.
37. KARAT, A. B. Low dose dapsone therapy in lepromatous leprosy. Lepr. Rev., 46(suppl.) 89-92, 1975.
38. LANGUILLON, J. Treatment of leprosy with clofazimine rifampicin and bayrena. Lepr. Rev., 46(suppl.): 81-84, 1975.
39. LEBAS, F. C.; HASS, C.; CHOUBRAC P. Heparotoxicité de l'association rifampicine-isoniazide. Antibiothérapie antituberculeuse. Etude analytique. Poumon lère Ed. 11.1976-C.
40. LEIKER D. L. Chemotherapy in leprosy. Int. J. Dermatol., 14(4) : 254-262, 1975.
41. LEIKER, D. L. Effect of mono treatment and combined treatment on the morphology of Myco-leprae in the skin. Lepr. Rev., 46 (suppl.): 73-79, 1975.
42. L EN Z IN I , L . Immunitá all'infezione: problematica ancora attuale. G. Batteriol. Virol. Immunol., 67(7-12): 308-316, 1974.
43. LEVY, L. Treatment failure in leprosy. Public Health Service Hospital, San Francisco. Int. J. Lepr., 44(1/2): 177-182, 1976.
44. LEVY, L.; SHEPARD, C. C.; FASAL, P. The bactericidal effect of rifampicin on M. leprae in man: a) single doses 600, 900 and 1200 mg and b) baily doses of 300 mg. Int. J. Lepr., 44(1/2): 183-187, 1976.
45. MANSFIELD, R. E. Tissue concentrations of clofazimine (B663) in man. Am. J. Trop. Med. Hyg., 23(6): 1116-1119, 1974.
46. MAYNARD, E. A.; SCHULTZ, R. L.; PEASE, D. C. Electron microscope of the vascular bed of rat cerebral cortex. Am. J. Anatol., 100(3): 409-433, 1957.
47. MEHRA, N. K.; DASGUPTA, A.; VAIDYA, M. C. An evaluation of the immune state in leprosy. Leprosy India, 48(3): 231-237, 1976.
48. MORRISON, N. E. & MARLEY, G. M. The mode of action of clofazimine. DNA blinding studies. Int. J. Lepr. 44(1/2): 133-134, 1976.
49. OPROMOLLA, D.V.A. & TONELLO, C. J. S. Antibiotics in leprosy, with special reference to rifampicin. Lepr. Rev., 46(suppl.): 141-145, 1975.
50. PAUNESCU, E. In vivo and in vitro suppression of humoral and cellular immunological response by rifampicin. Nature, 228: 1188-1190, 1970.
51. PEARSON, J. M. H.; REES, R. J. W.; WATERS, M. F. S. Sulphone resistance in leprosy. Lancet, 2(7924). 69-72, 1975.
52. PETERS, J. H. Carcinogenic activity of dapsone. Int. J. Lepr., 44(3): 383-384, 1976.
53. PFALTZGRAFF, R. E. The control of neuritis in leprosy with clofazimine. Int. J. Lepr., 40(4): 392-398, 1972.
54. RAMANUJAM, K.; IYER, C. G. S.; RAMU, G. A report on a controlled clinical trial with conventional and one third conventional dose of dapsone administered orally once a week in lepromatous patients. Lepr. Rev., 46(suppl.): 93-97, 1975.
55. RAMPEN, F. Rifampicin in the treatment of reactions in leprosy. Lepr. Rev., 47:75-76, 1976.
56. REA, T. H. & LEVAN, N. E. Erythema nodosum leprosum in a general hospital. Arch. Dermatol., 111(12) : 1575-1580, 1975.
57. REES, R. J. W. Rifampicin: the investigations of a bactericidal antileprosy drug. Lepr. Rev., 46(suppl.): 121-124, 1975.
58. REES, R. J. W.; WATERS, W. F. R.; PEARSON, J. M. H.; HELMY, H. S.; LAING, A. B. G. Long-term treatment of dapsone-resistant leprosy with rifampicin: clinical and bacteriological studies. Int. J. Lepr., 44(1/2): 159-169, 1976.
59. RUBEN, F. L.; WINKELSTEIN, A.; FOTIADIS, I. G.; DESSAUER, P. Rifampicin and immunosuppression. Lancet, 2(7835): 978, 1973.
60. SANSARRICQ, H.; TORRIGIANI, G.; WALTER, J,; REES, R. J. W. The WHO program for research on immunology of leprosy (IMMLEP). Int. I. Lepr., 44(1/2): 276-283, 1976.
61. SERROU, B.; SOLASSOL, C.; KARCENTY, L.; JOYEUX, H.; PUJOL, H. Action immunodépressive de la rifampicine. Nouv. Presse Med., /(19): 1295, 1972.
62. SHEPARD, C. C. Rifampicin therapy of lepromatous leprosy. Am. 1. Trop. Med. Hyg., 24(3): 475-484, 1975.
63. SHEPARD, C. C.; ELLARD, G. A.; LEVY, L.; OPROMOLLA, D. V. A.; PATTYN, S. R.; PETERS, J. H.; REES, R. J. W.; WATERS, M. F. R. Chimiothérapie experimentale de la lèpre. Bull. WHO, 54(3): 235-244, 1976.
64. SHER, R.; HOLM, G.; KOK, S. K.; KOORNHOF, H. J.; GLOVER, A. T and CR -I- lymphocyte profile in leprosy and the effect treatment. Infec. Immun., 13(1): 23-35, 1976.
65. SHESKIN, J. The case for invisible leprosy. J. Int. Dermatol., 14(5): 345-346, 1975.
66. SIBILLE, M. Tableau de famille des antibiotiques ou comment choisir votre antibiotique. Cah. Med., /(22): 1493-1515, 1976.
67. STEVENSON, R. D. Mechanism of anti-inflammatory. Action of glucocorticosteroids. Lancet, 1(8005): 225-226, 1977.
68. USTACELEBI, S. & WILLIAMS, J. F. Depression of interferon production in chick embryo cells by rifampicin. 1. Gen. Viral., 15: 139-148, 1972.
69. VILDE, J. L. Les associations d'antibiotiques. Encyclopédie Médico-Chir.
70. YAMADA, S. & KAZUYOSHI, I. Induction of hepatic ortiso-6-hydroxylase by rifampicin. Lancet, 2(7981): 366-367, 1976.
71. YOUMANS, S.; YOUMANS, G. P.; CAHALL, D. Effect of rifampicin on immunity to tuberculosis and on delayed hypersensitivity to purified protein derivative. Infect. Immun. 3(1): 127-132, 1976.
Esta revista tiene la licencia Creative Commons Attribution 4.0 International License.
Descargas
Los datos de descargas todavía no están disponibles.
